- How Long Does Nicotine Remain in Your System?
- The Best Time of Day to Drink Bone Broth to Maximize Health Benefits
- 8 Ways to Increase Dopamine Naturally
- 7 Best Breads for Maintaining Stable Blood Sugar
- Gelatin vs. Collagen: Which is Best for Skin, Nails, and Joints?
- The Long-Term Effects of Daily Turmeric Supplements on Liver Health
- Could Your Grocery Store Meat Be Causing Recurring UTIs?
- Are You Making This Expensive Thermostat Error This Winter?
- Recognizing the Signs of Hypothyroidism
- 10 Strategies to Overcome Insomnia
FDA Requiring Stronger Safety Labels for Opioid Medications
The U.S. Food and Drug Administration announced it will now be requiring updated safety labels for all opioid pain medications to better highlight the risks of long-term use, including misuse, addiction, and overdose.
The updated FDA opioid safety labeling is based on new data from two large postmarketing observational studies, which showed serious risks from long-term use. Citing these findings, public input, and the lack of strong evidence supporting long-term effectiveness, the FDA is updating opioid safety labels to support treatment decisions based on the latest evidence.
“The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. “This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring so that nothing like this ever happens again.”
The labeling changes will include clearer risk information; stronger dosing warnings; clarified use limits, including removing language that could be misinterpreted as supporting indefinite use; and treatment guidance, emphasizing that long-acting opioids should only be used when other treatments, including short-acting opioids, are ineffective.
The labels will also address safe discontinuation; overdose reversal agents; drug interactions, including combining opioids with gabapentinoids; additional risks with overdose, highlighting new information on postoverdose toxic leukoencephalopathy; and digestive health, including updates about possible esophageal complications.
The FDA is also requiring a new randomized, controlled clinical trial to directly assess the benefits and risks of long-term opioid use. The agency says it will closely monitor the trial’s progress.
Source: HealthDay
Copyright © 2026 HealthDay. All rights reserved.










